Search Result

Results for "

Antitumor efficacy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Payload (2) Akt (11) Amino acid Transporter (1) AMPK (3) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (2) Antibiotic (8) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (113) Arf Family GTPase (1) Atg8/LC3 (1) ATM/ATR (1) Aurora Kinase (4) AUTACs (1) Autophagy (8) Bacterial (11) Bcl-2 Family (4) Bcr-Abl (1) BCRP (1) Biochemical Assay Reagents (2) Btk (1) c-Fms (2) c-Kit (4) c-Met/HGFR (7) c-Myc (4) Calcium Channel (1) Carbonic Anhydrase (3) Casein Kinase (2) Caspase (4) CD73 (1) CDK (8) Cholinesterase (ChE) (1) ClpP (2) COX (1) Cytochrome P450 (5) Deubiquitinase (3) Dihydroorotate Dehydrogenase (1) Discoidin Domain Receptor (2) DNA Methyltransferase (1) DNA-PK (1) DNA/RNA Synthesis (12) Drug Derivative (6) Drug-Linker Conjugates for ADC (3) DYRK (2) E1/E2/E3 Enzyme (1) EAAT (1) EGFR (17) Endogenous Metabolite (9) Epigenetic Reader Domain (4) ERK (7) Estrogen Receptor/ERR (10) Eukaryotic Initiation Factor (eIF) (1) FAK (2) Fatty Acid Synthase (FASN) (2) Ferroptosis (7) FGFR (10) FLT3 (10) Fluorescent Dye (1) Fungal (4) Galectin (1) GLP Receptor (1) GLUT (2) Glutaminase (1) Glutathione Peroxidase (2) HDAC (14) Heme Oxygenase (HO) (1) Histamine Receptor (1) Histone Acetyltransferase (2) Histone Demethylase (5) Histone Methyltransferase (4) HIV (6) HSP (9) HSV (1) HuR (1) IFNAR (1) IGF-1R (2) IKK (2) IKZF Family (1) Indoleamine 2,3-Dioxygenase (IDO) (3) Insecticide (1) Interleukin Related (4) IRAK (1) Isotope-Labeled Compounds (3) Itk (1) JAK (4) JNK (1) Keap1-Nrf2 (2) Kinesin (2) Lipocalin Family (1) Lipoxygenase (1) LXR (1) MAP4K (4) MDM-2/p53 (9) MEK (2) Methylenetetrahydrofolate Dehydrogenase (MTHFD) (1) MHC (1) Microtubule/Tubulin (19) Mitochondrial Metabolism (6) MMP (4) MNK (1) Molecular Glues (3) Monoamine Oxidase (4) Mps1 (2) mTOR (4) N-myristoyltransferase (1) NAMPT (1) Necroptosis (1) NEKs (2) NF-κB (16) NOD-like Receptor (NLR) (1) Notch (1) NTPDase (1) Orexin Receptor (OX Receptor) (1) P-glycoprotein (2) P2X Receptor (1) p38 MAPK (7) PAI-1 (2) PAK (1) PARP (10) PD-1/PD-L1 (12) PDGFR (4) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phosphodiesterase (PDE) (2) Phospholipase (1) Photosensitizer (3) PI3K (6) PI4K (1) Pim (2) PKC (1) Polo-like Kinase (PLK) (3) Potassium Channel (4) Progesterone Receptor (1) PROTACs (23) Proteasome (2) Pyroptosis (1) Pyruvate Kinase (1) Quinone Reductase (1) Radionuclide-Drug Conjugates (RDCs) (2) Raf (3) Ras (6) Reactive Oxygen Species (ROS) (19) Reference Standards (8) RET (2) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROR (3) ROS Kinase (1) SARS-CoV (1) SHP2 (1) Sirtuin (3) Sodium Channel (1) Somatostatin Receptor (1) SOS1 (1) Src (1) STAT (10) Stearoyl-CoA Desaturase (SCD) (1) STING (8) Survivin (1) TAM Receptor (3) Telomerase (1) TGF-β Receptor (2) Tim3 (1) TNF Receptor (5) Toll-like Receptor (TLR) (2) Topoisomerase (6) Transmembrane Glycoprotein (1) Trk Receptor (5) TRP Channel (1) TrxR (2) VD/VDR (1) VEGFR (17) Wnt (1) YAP (5) β-catenin (5)
By Research Areas:	Cancer (365) Cardiovascular Disease (4) Endocrinology (1) Infection (21) Inflammation/Immunology (39) Metabolic Disease (1) Neurological Disease (4)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (4)
Oligonucleotides:	Nucleoside Analogs (1)

368

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-161078

QP5038	Amyloid-β	Cancer
QP5038 (compound 28) is an inhibitor of QPCTL with an IC₅₀ value of 3.8 nM. QP5038 has *antitumor* efficacy .

HY-130115

IACS-8803	STING	Cancer
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .

HY-164484

IHMT-RAF-128	Raf	Cancer
IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities .

HY-155647

Microtubule stabilizing agent-1	Microtubule/Tubulin	Cancer
Microtubule stabilizing agent-1 (compound 3l) is a Paclitaxel derivative that efficiently promotes tubulin polymerization. Microtubule stabilizing agent-1 shows antitumor efficacy .

HY-173065

CDK9-IN-36	CDK Apoptosis	Cancer
CDK9-IN-36 (Compound T7) is a potent, selective and metabolically stable CDK9 inhibitor with an IC₅₀ value of 1.2 nM. CDK9-IN-36 effectively suppresses cell proliferation, reduces colony formation, and induces apoptosis in Osimertinib (HY-15772)-resistant NSCLC cells by downregulating Mcl-1. CDK9-IN-36 also demonstrates antitumor efficacy in a tumor xenograft model .

HY-146034

NOD1/2 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC₅₀ values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T_1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-121349

Aerothionin	Bacterial Fungal Antibiotic	Infection Cancer
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-130116

IACS-8779	STING	Cancer
IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .

HY-161077

QP5020	Amyloid-β	Cancer
QP5020 (compound 28) is an inhibitor of QPCTL with an IC ⁵⁰ value of 15 nM. QP5020 has *antitumor* efficacy .

HY-115833

Histamine H4 receptor antagonist-2	Histamine Receptor	Cancer
Histamine H4 receptor antagonist-2 serves as a potent activator of p53, demonstrating significant antitumor efficacy.

HY-162449

GIC-20	Apoptosis Ferroptosis	Cancer
GIC-20 is a dual inducer for apoptosis and ferroptosis. GIC-20 exhibits antitumor efficacy against fibrosarcoma .

HY-157302

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-123891

NS-062	EGFR	Cancer
NS-062 is an orally active, irreversible targeted covalent inhibitor for EGFR, and exhibits antiproliferative efficacy in drug-resistant double mutated H1975 cell with an IC₅₀ of 0.19 μM. NS-062 exhibits antitumor efficacy in mouse H1975 xenograft model .

HY-130115A

IACS-8803 disodium 1 Publications Verification	STING	Cancer
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .

HY-130115B

IACS-8803 diammonium 1 Publications Verification	STING	Cancer
IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .

HY-155020

Antitumor agent-101	Histone Methyltransferase GLP Receptor	Cancer
Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC₅₀s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-133117A

(Rac)-BAY-985	IKK	Cancer
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective TBK1 inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy .

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious RAF inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .

HY-150256

YTP-17	YAP	Cancer
YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC₅₀ of 4 nM. YTP-17 shows anti-tumor efficacy .

HY-101096

Suvecaltamide MK-8998; CX-8998; JZP385	Calcium Channel	Neurological Disease Cancer
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .

HY-P10255

K90-114TAT	Potassium Channel	Cancer
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas .

HY-162085

Axl-IN-17	TAM Receptor	Cancer
Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC₅₀ value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .

HY-164386

Defoslimod OM 174	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Defoslimod (OM 174) is an agonist for TLR4 receptor and acts as an immunomodulator. Defoslimod activates macrophages and dendritic cells, induces cytokines secretion, and exhibits antitumor efficacy in rats .

HY-163768

Antitumor agent-172	β-catenin	Inflammation/Immunology Cancer
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC₅₀ of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with K_d of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .

HY-120885

(+)-Oxanthromicin	Ras	Cancer
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-164959

ZINC00230567	Lipocalin Family	Cancer
ZINC00230567 is an inhibitor for Lipocalin-2 (LCN2). ZINC00230567 reduces the colony formation and cell viability of cell SUM149, and exhibits anti-tumor efficacy .

HY-13303

RO 4927350	MEK	Cancer
RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models .

HY-155146

Anticancer agent 146	Necroptosis	Cancer
Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .

HY-170432

PARP1-IN-34	PARP	Cancer
PARP1-IN-34 (compound 30) is a selective PARP1 inhibitor with an IC₅₀ of 0.32 nM. PARP1-IN-34 is a subnanomolar PARP1 inhibitor with >1000-fold selectivity against PARP2 with an IC₅₀ of 326 nM. PARP1-IN-34 shows antitumor efficacy_[1].

HY-130116A

IACS-8779 disodium	STING	Cancer
IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .

HY-138799A

KA2507 monohydrochloride	HDAC	Inflammation/Immunology Cancer
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC₅₀=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects .

HY-116447

Antitumor agent-159	Mitochondrial Metabolism Apoptosis	Cancer
Antitumor agent-159 (Compound 13b) targets the mitochondria and downregulates cardiolipin levels. Antitumor agent-159 inhibits the proliferation of cancer cell MDA-MB-231, arrests the cell cycle at sub-G1 phase, and induces apoptosis in MDA-MB-231. Antitumor agent-159 exhibits antitumor efficacy in MDA-MB-231 xenograft mouse models .

HY-146231

SS47	PROTACs MAP4K	Inflammation/Immunology Cancer
SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy .

HY-115690

K-TMZ	Drug Derivative	Cancer
K-TMZ is a derivative of methyl ketone, which exhibits antitumor efficacy against O ⁶ -methylguanine DNA methyltransferase (MGMT) deficient cell. K-TMZ can be used for research of glioblastoma .

HY-13646C

Encequidar mesylate hydrochloride HM30181 mesylate hydrochloride; HM30181A mesylate hydrochloride	P-glycoprotein	Cancer
Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models .

HY-163766

Antiproliferative agent-51	Estrogen Receptor/ERR	Cancer
Antiproliferative agent-51 (Compound 18h) exhibits inhibitory efficacy against estrogen receptor α (ERα) mediated transcription, with an IC₅₀ of 1.6 nM. Antiproliferative agent-51 inhibits the proliferation of cancer cell ZR-75, with an IC₅₀ of 0.031 μM. Antiproliferative agent-51 exhibits antitumor efficacy in mouse models .

HY-176508

KDX1381	Casein Kinase	Cancer
KDX1381 is a bivalent CK2α inhibitor (IC₅₀: 17 nM, K_D: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent HDAC inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-W402682

SXC2023	Amino acid Transporter	Neurological Disease Cancer
SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export .

HY-159642

TYRA-300	FGFR	Cancer
TYRA-300 is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM in Ba/F3. TYRA-300 exhibits antitumor efficacy against urothelial cancers and solid tumors .

HY-149717

Antitumor agent-122	Others	Cancer
Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC₅₀ values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .

HY-146465

Anticancer agent 60	Microtubule/Tubulin	Cancer
Anticancer agent 60 (compound 3h) has antiproliferative activity against human HepG2 cells (IC₅₀ = 4.13 μM) and presents antitumor efficacy in a human HepG2 xenograft mouse model .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-128222

Selenosemicarbazide Hydrazinecarboselenoamide	Bacterial	Infection Cancer
Selenosemicarbazide (Hydrazinecarboselenoamide) exhibits antimicrobial activity, that inhibits B. subtilis, S. aureus, Klebsiella pneumoniae, Sarcina lutea and Mycobacterium tuberculosis. Selenosemicarbazide forms complex with metal ions, and exhibits antitumor efficacy against cancer cells

HY-170436

NFh-NMe-2	Photosensitizer Apoptosis	Cancer
NFh-NMe-2 is a photosensitizer, that interacts with nitroreductase, generates singlet oxygen in tumor cells, exhibits cytotoxicity in cancer cells, and induces apoptosis. NFh-NMe-2 exhibits antitumor efficacy in mouse models .

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent HDAC inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-176249

Tetrazanbigen TNBG	Apoptosis	Cancer
Tetrazanbigen is a potent and selective antitumor agent. Tetrazanbigen exhibits strong antitumor efficacy against six human cancer cell lines with an IC₅₀ range of 2.13-8.01 μg/mL and an IC₅₀ of 11.25 μg/mL against normal hepatocytes. Tetrazanbigen induces S phase arrest and apoptosis in QGY-7701 cells. Tetrazanbigen exerts its antitumor activity by inducing lipid accumulation accumulation in cancer cells .

HY-175214

Antitumor photosensitizer-9	Reactive Oxygen Species (ROS) Photosensitizer	Cancer
Antitumor photosensitizer-9 is a near-infrared Photosensitizer (PS) with a high singlet oxygen production rate (relative rate = 1.79). Antitumor photosensitizer-9 exhibits strong phototoxicity against various cancer cells and induces ROS generation under light irradiation. Antitumor photosensitizer-9 inhibits tumor growth in vivo and exhibits excellent anticancer photodynamic therapy (PDT) efficacy at low drug and light doses. Antitumor photosensitizer-9 can be used in photodynamic therapy research .

Cat. No.	Product Name	Type

HY-D2620

CAR-2	Fluorescent Dyes/Probes
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC₅₀ of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models .

HY-159642G

TYRA-300 (GMP)	Fluorescent Dye
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

Cat. No.	Product Name	Type

HY-159642G

TYRA-300 (GMP)	Biochemical Assay Reagents
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

Cat. No.	Product Name	Target	Research Area

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Peptides	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-N6693

Valinomycin 5+ Cited Publications NSC 122023	Apoptosis Antibiotic Autophagy Fungal	Infection Others Cancer
Valinomycin is a potassium-specific ionophore, the valinomycin-K ⁺ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K ⁺ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .

HY-P10439

CVRARTR	PD-1/PD-L1	Inflammation/Immunology Cancer
CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .

HY-P10255

K90-114TAT	Potassium Channel	Cancer
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-P10930A

wrwycr-NH2 TFA	DNA/RNA Synthesis	Cancer
wrwycr-NH2 (TFA) is a peptide. wrwycr-NH2 (TFA) is cytotoxic to multiple cancer cells, can induce DNA damage and cell cycle arrest, but does not induce endoplasmic reticulum stress. wrwycr-NH2 (TFA) has anti-tumor activity, and it shows better efficacy when used in combination with DNA-damaging agents .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits PD-1/PD-L1 interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), HDAC3 (IC₅₀=9.18 nM), HDAC6 (IC₅₀=42.7 nM), HDAC8 (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

HY-P10925

Zolucatetide FOG-001; I-66	β-catenin	Cancer
Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC₅₀ of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .

HY-P11058

OVA(250-264) OVAp	MHC	Cancer
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 ⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .

HY-169089A

RP-182-PEG3-K(palmitic acid) TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid) (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid) TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid) TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-169089

RP-182-PEG3-K(palmitic acid)	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10925A

(Z)-Zolucatetide (Z)-FOG-001; I-67	β-catenin	Cancer
(Z)-Zolucatetide ((Z)-FOG-001; I-67), a structural isomer of Zolucatetide (HY-P10925), is a potent β-catenin inhibitor with an IC₅₀ of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .

HY-P10870

Pep1-DNP conjugate 9	Peptide-Drug Conjugates (PDCs) FGFR Apoptosis	Cancer
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with K_D of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Target	Research Area

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .

HY-P99320

Tarextumab OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody	Notch	Cancer
Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P99493

Cantuzumab ravtansine IMGN242; huC242-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P990259

Anti-Mouse CD96 Antibody (3.3)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-Mouse CD96 Antibody (3.3) is a rat-derived anti-mouse CD96 IgG1 λ type antibody inhibitor. Anti-Mouse CD96 Antibody (3.3) blocks binding of CD155 to CD96. Anti-Mouse CD96 Antibody (3.3) can enhance the antitumor efficacy of multiple immune-checkpoint inhibitors. Anti-Mouse CD96 Antibody (3.3) shows potent anti-tumor and anti-metastatic activity in various tumor models. Anti-Mouse CD96 Antibody (3.3) can be used for the researches of cancer and inflammation, such as mammary carcinoma .

HY-P99712

Lonigutamab hz208F2-4	IGF-1R Apoptosis ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases sup>[2].

HY-P990068

Perenostobart SRF617	NTPDase	Inflammation/Immunology Cancer
Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC₅₀ values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 ⁺ T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .

HY-P99382A

Vopratelimab (Mouse IgG2a)	Inhibitory Antibodies	Cancer
Vopratelimab (Mouse IgG2a) is a monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy .

HY-P991613

BGB-A445	Orexin Receptor (OX Receptor) NF-κB	Cancer
BGB-A445 is a humanized non-ligand-blocking agonistic OX40 monoclonal antibody with high affinity to OX40. BGB-A445 activates downstream NF-κB pathway to induce immune cell activation, proliferation, and survival. BGB-A445 dose-dependently and significantly depletes regulatory T cells via antibody-dependent cellular cytotoxicity (ADCC). BGB-A445 demonstrates robust and dose-dependent antitumor efficacy in the MC38 mice models. BGB-A445 can be used for the researches of cancer, such as colon adenocarcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8342

Rhamnazin 1 Publications Verification	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-N7128

Flavanone	Structural Classification Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Sophora flavescens Aiton Plants Disease Research Fields Cancer	Cytochrome P450 ERK p38 MAPK NF-κB MMP PAI-1
Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). Flavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .

HY-114977

Avenanthramide A	Structural Classification Avena sativa Linn. Gramineae Source classification Phenols Polyphenols Plants	Reactive Oxygen Species (ROS) Apoptosis
Avenanthramide A is a phytoalexin, which can be found in oats (Avena sativa L.). Avenanthramide A targets the RNA helicase DDX3, leads to mitochondrial swelling and increased ROS production, and induces apoptosis in CRC cells. Avenanthramide A exhibits antitumor efficacy in mouse model. Avenanthramide A orally active .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Structural Classification Animals Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-121349

Aerothionin	Structural Classification Antibiotics Marine natural products Source classification Sponge	Bacterial Fungal Antibiotic
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-120885

(+)-Oxanthromicin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Ras
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-121104

Bactobolin	Structural Classification Natural Products Microorganisms Source classification	Antibiotic Bacterial
Bactobolin (Compound 1) is an antibiotic, which inhibits Escherichia coli, Salmonella, Shigella, Staphylococcus and Bacillus subtilis, with MICs of 0.3-6.25 μg/mL. Bactobolin exhibits antitumor efficacy against leukemia, with a LD₅₀ value of 6.25-12.5 mg/kg .

HY-129331

Neothramycin A	Structural Classification Microorganisms Antibiotics Source classification	Antibiotic Bacterial Fungal
Neothramycin A is an antibiotic, which can be isolated from Streptomyces. Neothramycin A exhibits board spectrum antimicrobial activity, inhibits Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli W677, and Saccharomyces cerevisia with MIC of 25-50 μg/mL. Neothramycin A exhibits antitumor efficacy against leukemia in mouse models .

HY-110151

Bengamide B	Structural Classification Alkaloids Other Alkaloids Marine natural products Source classification Sponge	NF-κB Interleukin Related
Bengamide B is an inhibitor for NF-κB with an IC₅₀ of 85 nM. Bengamide B inhibits LPS (HY-D1056)-induced expression of TNF-α, IL-6 and MCP-1, exhibits anti-inflammatory activity. Bengamide B exhibits antitumor efficacy (IC₅₀ for HCT-116 is 2 nM) .

HY-N7128R

Flavanone (Standard)	Structural Classification Flavonoids Leguminosae Flavonones Source classification Sophora flavescens Aiton Plants	Cytochrome P450 Reference Standards ERK p38 MAPK NF-κB MMP PAI-1
Flavanone (Standard) is the analytical standard of Flavanone. This product is intended for research and analytical applications. Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). lavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .

HY-114977R

Avenanthramide A (Standard)	Structural Classification Avena sativa Linn. Gramineae Source classification Phenols Polyphenols Plants	Reference Standards Reactive Oxygen Species (ROS) Apoptosis
Avenanthramide A (Standard) is the analytical standard of Avenanthramide A. This product is intended for research and analytical applications. Avenanthramide A is a phytoalexin, which can be found in oats (Avena sativa L.). Avenanthramide A targets the RNA helicase DDX3, leads to mitochondrial swelling and increased ROS production, and induces apoptosis in CRC cells. Avenanthramide A exhibits antitumor efficacy in mouse model. Avenanthramide A orally active .

HY-125620

Rubiginone D2	Quinones Structural Classification Microorganisms Anthraquinones Source classification	Antibiotic Bacterial
Rubiginone D2 is an antibiotic, which exhibits antimicrobial activities against Bacillus subtilis, Staphylococcus aureus and Escherichia coli. Rubiginone D2 exhibits antitumor efficacy, inhibits proliferations of cancer cells HM02, Kato III, HepG2 and MCF7, with GI₅₀s of 0.1, 0.7, <0.1 and 7.5 μM, respectively .

HY-N6693

Valinomycin 5+ Cited Publications NSC 122023	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Apoptosis Antibiotic Autophagy Fungal
Valinomycin is a potassium-specific ionophore, the valinomycin-K ⁺ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K ⁺ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .

HY-126170

Valanimycin	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Antibiotic Bacterial
Valanimycin is an antibiotic, which inhibits Escherichia coli (BE1121) through interaction with DNA. Valanimycin exhibits cytotoxicity to mouse leukemia L1210, P388/S (doxorubicin (HY-15142A)-sensitive), and P388/ADR (doxorubicin-resistant), with IC₅₀ of 0.79, 2.65, and 1.44 μg/mL, respectively. Valanimycin exhibits antitumor efficacy against ehrlich ascites tumors or L1210 in mice .

HY-N12124

Monascuspiloin Monascinol	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

HY-133541

Glucopiericidin A	Classification of Application Fields Disease Research Fields Cancer	GLUT ADC Payload Apoptosis
Glucopiericidin A is a natural piericidin compound obtained from a marine-derived Streptomyces strain. Glucopiericidin A serves as a glucose transporter (GLUT) chemical probe and suppresses glycolysis. Glucopiericidin A inhibits ATP-dependent filopodia protrusion with Piericidin A (PA; HY-114936) and has no effect alone. Glucopiericidin A induces cell apoptosis through reducing the reactive oxygen species (ROS) level by increasing PRDX1 and exhibits potent antitumor efficacy in ACHN mice xenografts .

HY-N0492

α-Lipoic Acid Maximum Cited Publications 10 Publications Verification Thioctic acid; (±)-α-Lipoic acid; DL-α-Lipoic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-N0492A

α-Lipoic Acid sodium Maximum Cited Publications 10 Publications Verification Thioctic acid sodium; (±)-α-Lipoic acid sodium; DL-α-Lipoic acid sodium	Infection Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-N0492AR

α-Lipoic Acid sodium (Standard) Thioctic acid sodium (Standard); (±)-α-Lipoic acid sodium (Standard); DL-α-Lipoic acid sodium (Standard)	Natural Products Source classification Endogenous metabolite	Reference Standards NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (sodium) (Standard) is the analytical standard of α-Lipoic Acid (sodium). This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation. α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells. α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1.

HY-N1934

Dihydroberberine	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields	Potassium Channel HSP
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-N3389

Licoisoflavone A 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on SARS-CoV-2 infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and SARS-CoV-2 infection .

HY-N0492R

α-Lipoic Acid (Standard) Maximum Cited Publications 10 Publications Verification Thioctic acid (Standard); (±)-α-Lipoic acid (Standard); DL-α-Lipoic acid (Standard)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Reference Standards NF-κB HIV Mitochondrial Metabolism Endogenous Metabolite Apoptosis
α-Lipoic Acid (Standard) is the analytical standard of α-Lipoic Acid. This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation . α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells . α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1 .

HY-N7694

Isotoosendanin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-108052

Delphinidin 3-glucoside chloride 1 Publications Verification Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Classification of Application Fields Hibiscus sabdariffa Linn. Source classification Plants Disease Research Fields Cancer	EGFR Apoptosis Akt
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-N1934R

Dihydroberberine (Standard)	Alkaloids Structural Classification other families Source classification Plants Isoquinoline Alkaloids	Reference Standards Potassium Channel HSP
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-108052R

Delphinidin 3-glucoside chloride (Standard) Delphinidin 3-O-glucoside chloride (Standard); Delphinidin 3-O-β-glucoside chloride (Standard)	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Hibiscus sabdariffa Linn. Source classification Plants	Reference Standards EGFR Apoptosis Akt
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-113382R

N-Methylhydantoin (Standard) 1-Methylhydantoin (Standard)	Alkaloids Structural Classification Other Alkaloids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-W015490S

1,4-Naphthoquinone-d6

1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone. 1,4-Naphthoquinone is an inhibitor with broad-spectrum inhibitory activity targeting DNA polymerase, NF-κB and monoamine oxidase (MAO-A/B), with antibacterial and anti-biofilm efficacy. 1,4-Naphthoquinone is a competitive inhibitor of MAO-B (Ki=1.4 μM) and a non-competitive inhibitor of MAO-A (Ki=7.7 μM). 1,4-Naphthoquinone inhibits DNA polymerase pol α, β, γ, δ, ε, λ with IC₅₀ ranging from 5.57-128 μM. 1,4-Naphthoquinone inhibits tumor cell proliferation, induces apoptosis and necrosis, and has anti-angiogenic and anti-inflammatory activities by inducing oxidative stress, depleting glutathione (GSH), inhibiting DNA polymerase-mediated DNA synthesis and blocking NF-κB nuclear translocation. 1,4-Naphthoquinone can be used in anti-bacterial , anti-tumor and anti-inflammatory studies, including inhibition of melanoma and colon cancer cell growth and endothelial cell function, as well as LPS-induced inflammation models .

HY-10977S

Tivozanib-d6
Tivozanib-d₆ (AV-951-d₆) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .

Cat. No.	Product Name		Classification

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-146231A

SS47 TFA		PROTAC Synthesis
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.